Drug Trial Radar · NCT05834803
Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 26, 2023
Primary completion
Jun 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- University of AarhusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aarhus University Hospital; Copenhagen University Hospital, Rigshospitalet; Odense University Hospital; Aalborg University Hospital; Gødstrup Hospital; Holbaek Sygehus; Amsterdam UMC; The Augustinus Foundation, Denmark.; Novo Nordisk Foundation
- First posted
- Apr 28, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate whether percutaneous transluminal renal angioplasty (PTRA) with stent placement of atherosclerotic renal artery stenosis is beneficial in high-risk patients selected according to the criteria used in the DAN-PTRAI study. The main questions the trial aims to answer are whether renal artery stenting in addition to optimal medical therapy, compared with a sham procedure and optimal medical therapy, has beneficial effects on: * Blood pressure (primary outcome: 24-hour ambulatory systolic blood pressure at 6 months) * Kidney function * Hospitalizations for heart failure
Conditions
- Renovascular Hypertension
- Renovascular Hypertension With Renal Failure
- Heart Failure
- Renal Artery Stenosis Atherosclerotic
Interventions
Optimal medical therapy (OMT)Drug
Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.
Catheter-based angiographyDiagnostic test
Catheter-based angiography performed in accordance with the study protocol.
Measurement of translesional pressure gradientsDiagnostic test
Measurement of translesional pressure gradients performed in accordance with the study protocol.
Renal artery stentingProcedure
Renal artery stenting performed in accordance with the study protocol.
Sham (No Treatment)Procedure
Sham procedure performed in accordance with the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in 24-hour ambulatory systolic blood pressureTime frame: Baseline and 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Aarhus University Hospital
Aarhus N, Denmark · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Odense University Hospital
Odense C, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.